Skip to content
Precision for Medicine
Contact
Chicago - rétréci

Du vendredi 30 mai au mardi 3 juin

ASCO 2025

Stand #11059

Rejoignez notre équipe de direction et nos experts à Chicago

Accélérez votre développement oncologique grâce à un ORC intégré et conçu à cet effet. Precision associe une expertise scientifique à des opérations réactives sur plus de 2 500 essais terminés. Nos solutions cliniques et de laboratoire complètes transforment vos innovations en matière de cancer en thérapies qui changent la vie, en fournissant des résultats plus rapides et plus rentables.

Passez nous voir sur notre stand n° 11059 ouremplissez le formulaire ci-dessous pour prendre rendez-vous avec nos experts à l'ASCO.

Sofia Baig, Présidente, Solutions cliniques

La différence Precision

Chez Precision, nous nous engageons à être l'ORC le plus fiable du secteur, en tenant nos promesses avec une expertise et une transparence inébranlables. Notre équipe excelle dans la gestion d'essais complexes en oncologie, encourageant l'innovation et la collaboration interfonctionnelle afin d'accélérer les délais de développement. En investissant dans des technologies de nouvelle génération, nous améliorons l'accès aux données cliniques, la prise de décision et les processus de rationalisation. Cet engagement permet de fournir efficacement des thérapies qui changent la vie, faisant de Precision un partenaire de confiance pour faire avancer la médecine et façonner l'avenir de la médecine.

Rencontrez nos cadres dirigeants

  • Margaret Keegan

    Margaret Keegan

    Chief Executive Officer, Precision Medicine Group

  • Chad_Clark_Resize

    Chad Clark

    President and Chief Operating Officer, Precision Medicine Group

  • Matt Grow 1

    Matt Grow

    Chief Commercial Officer, Precision for Medicine

  • Matt-Arnold-1

    Matt Arnold

    President, Translational Sciences, Precision for Medicine

  • Harpreet-Singh2

    Harpreet Singh, MD

    Chief Medical Officer, Precision for Medicine

  • Deb Phippard

    Deborah Phippard, PhD

    Chief Scientific Officer, Precision for Medicine

  • Darren Davis

    Darren Davis, PhD

    Senior Vice President, Translational Sciences, Precision for Medicine

  • Andrea Cotton

    Andrea Cotton-Berry

    Global Head of Strategic Development, Precision for Medicine

Réservez du temps avec nos experts !

Contactez-nous en utilisant le formulaire ci-dessous et notre équipe vous contactera pour organiser une réunion dédiée à l'ASCO.

Retrouvez Precision for Medicine au stand n° 11059

ASCO 2025

McCormick Place, 2301 S Martin Luther King Dr, Chicago, IL 60616, États-Unis

Heures d'exposition :

31 mai - 2 juin - 09h00 - 17h00

May 31 – June 2 - 09:00AM - 05:00PM

Harpreet Singh, MD, CMO et ancien directeur de la division oncologie de la FDA

Les autorisations de la FDA révolutionnent la recherche sur le cancer

2024 a été une année remarquable pour les traitements du cancer et des maladies rares, la FDA ayant approuvé plusieurs thérapies nouvelles et innovantes. Dans cette vidéo, le médecin en chef de Precision et ancien directeur de la division oncologie de la FDA, Harpreet Singh, MD, partage les trois principales approbations qui feront progresser le traitement du cancer en 2025.

Améliorer la phase précoce de l'oncologie avec des conceptions de phase 1-2 homogènes

Les experts interfonctionnels de Precision ont réalisé 46 essais oncologiques homogènes au cours des trois dernières années. Cet eBook contient des considérations clés et des bonnes pratiques fondées sur l'expérience du monde réel pour vous aider à naviguer sur le chemin qui vous attend.

  • Stratégie et planification des études préliminaires
  • Stratégies d'exécution
  • Sélection d'un ORC

Télécharger le livre électronique

Perspectives de développement en oncologie par les experts de Precision

Restez informé grâce aux dernières informations fournies par nos experts, qui partagent leurs connaissances, les tendances et les réussites dans le domaine de la recherche clinique.

En savoir plus
Read: Progress in Gastrointestinal Oncology: 5 Key Insights from ASCO GI Progress in Gastrointestinal Oncology: 5 Key Insights from ASCO GI

Clinical Trials

Progress in Gastrointestinal Oncology: 5 Key Insights from ASCO GI

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=178509987433, hs_child_table_id=0, hs_updated_at=1754641355019, hs_published_at=1757700235512, description=Ivan Barrera, MD is a fellowship-trained expert in Research GI Oncology with over 15 years of clinical research experience across various healthcare systems and facilities. He is a methodical and strategic key player in interdisciplinary drug development teams, specializing in medical monitoring. Dr. Barrera has extensive experience in solid tumors, particularly Gastrointestinal Oncology, including Neuroendocrine Tumors, and has worked on FIH and Phase I-IV studies. His industry clinical development experience spans small molecules, antibodies, vaccines, cytokines, oncolytic viruses, radiopharmaceuticals, and cellular therapies., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/IvanBarrera-1.png',altText='IvanBarrera-1',fileId=194126030114}, lastname=Barrera, hs_initial_published_at=1726512636738, hs_created_by_user_id=26433386, hs_created_at=1726500269983, hs_is_edited=false, hs_deleted_at=0, name=Ivan, job=Senior Medical Director, slug=ivan-barrera, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Ivan Barrera avatar

    Ivan Barrera
Découvrir
Read: Phase 1-2 Case Study: Oncology Trial Success and Proactive Partnership Phase 1-2 Case Study: Oncology Trial Success and Proactive Partnership

Clinical Trials - Early Phase Research - Oncology

Phase 1-2 Case Study: Oncology Trial Success and Proactive Partnership

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=169565849889, hs_child_table_id=0, hs_updated_at=1754641413972, hs_published_at=1757700235512, avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/tai-bibbs.png',altText='tai-bibbs',fileId=194123714175}, lastname=Bibbs, hs_initial_published_at=1718988967067, hs_created_by_user_id=26433386, hs_created_at=1717603645564, hs_is_edited=false, hs_deleted_at=0, name=Tai, job=Director, Project Management, slug=tai-bibbs, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Tai Bibbs avatar

    Tai Bibbs
Découvrir
Read: FDA's Vision for Multiregional Clinical Trials in Oncology FDA's Vision for Multiregional Clinical Trials in Oncology

Clinical Trials - Regulatory - Oncology

FDA's Vision for Multiregional Clinical Trials in Oncology

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=167363064857, hs_child_table_id=0, hs_updated_at=1719905898183, hs_published_at=1757700235512, description=Industry-leading oncologist and demonstrated medical leader in precision medicine, novel trial design and innovative regulatory initiatives designed to expedite drug approvals. Draws on nearly a decade leading oncology and rare disease programs at the FDA. Former fellow at the National Cancer Institute and frequent featured speaker at ASCO and AACR. CDER technical authority on oncologic drug and biological products for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors and rare tumors., avatar=Image{width=553,height=580,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Harpreet-Singh2.png',altText='Harpreet-Singh2',fileId=171747124346}, linkedin=https://www.linkedin.com/in/harpreetsinghmd/, team=[{id=163072475007, name='Precision for Medicine Leadership'}], lastname=Singh, MD, hs_initial_published_at=1715692570942, hs_created_by_user_id=2737751, hs_created_at=1715692477118, hs_is_edited=false, hs_deleted_at=0, name=Harpreet, job=Chief Medical Officer, slug=harpreet-singh, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Harpreet Singh, MD avatar

    Harpreet Singh, MD
Découvrir

Des capacités spécialisées à chaque étape du développement clinique

Tirer parti d'une infrastructure intégrée qui réduit les inefficacités inhérentes à un développement complexe. Intégrer l'exécution des laboratoires et des essais pour accélérer la mise sur le marché. Incorporer l'expertise en matière de fabrication pour les thérapies innovantes afin de garantir l'évolutivité. Precision peut personnaliser et faire converger ses capacités pour répondre aux besoins uniques de votre programme.

  • Discover Explorer
    soutien aux essais cliniques

    CRO mondial
    Services

    CRO primé avec une grande expertise en oncologie et en maladies rares

    Explorer
  • Discover Explorer
    Services de laboratoire spécialisés

    Laboratoire mondial
    Services

    Des sciences translationnelles et des sciences des biomarqueurs exceptionnelles avec des services de laboratoire central à l'échelle mondiale

    Explorer

Margaret Keegan
Margaret Keegan

Chief Executive Officer, Precision Medicine Group

Industry luminary, passionate about building tech-enabled and data-driven operational models that streamline development and access for much needed medicines. Former leader at the world’s largest and most successful CROs, as COO at PRA Health Services and President of IQVIA Clinical Development. Expert in the full range of clinical development functions including biostatistics, data, safety, regulatory, clinical development, and sales. Driven to enable leaders and teams to be their best and to deliver with excellence for our clients and the patients we serve.
Chad_Clark_Resize
Chad Clark

President and Chief Operating Officer, Precision Medicine Group

Recognized industry leader with deep expertise spanning biomarker-driven clinical development, patient access and global market access. In addition to the role at Precision Medicine Group, Chad is also President of Precision for Medicine. In prior roles he has served as Chief Operating Officer of United BioSource Corporation and founder of DataPhaseIV. Proven ability to scale operations in response to client needs, adding the end-to-end capabilities necessary to support development and patient access to today’s complex therapies.
Matt Grow 1
Matt Grow

Chief Commercial Officer, Precision for Medicine

Visionary leader with a strong track record of fostering growth through commercial innovation and excellence. Drives sales by evolving the go-to-market model, landing and expanding key customer segments, and strengthening active client relationships. Proven expertise in biotech and pharmaceutical development spanning executive management, strategy, business development, sales, marketing and account management.
Matt-Arnold-1
Matt Arnold

President, Translational Sciences, Precision for Medicine

Strategic, highly collaborative biotechnology industry veteran, driven by opportunities to bring life-changing therapeutics to patients. Over two decades of global, cross-functional biotech and pharmaceutical experience, across both rapid growth and mature organizations, including leadership positions at AVROBIO, AstraZeneca, and Amgen.
Harpreet-Singh2
Harpreet Singh, MD

Chief Medical Officer, Precision for Medicine

Industry-leading oncologist and demonstrated medical leader in precision medicine, novel trial design and innovative regulatory initiatives designed to expedite drug approvals. Draws on nearly a decade leading oncology and rare disease programs at the FDA. Former fellow at the National Cancer Institute and frequent featured speaker at ASCO and AACR. CDER technical authority on oncologic drug and biological products for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors and rare tumors.
Deb Phippard
Deborah Phippard, PhD

Chief Scientific Officer, Precision for Medicine

Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy.
Darren Davis
Darren Davis, PhD

Senior Vice President, Translational Sciences, Precision for Medicine

Visionary leader with decades of distinguished biotechnology and clinical translational research experience. Founded ApoCell in 2004 and later was instrumental in developing and commercializing the ApoStream® rare-cell liquid biopsy technology. Globally recognized cancer researcher and the author of more than 100 peer-reviewed publications. Dedicated and committed to improving the lives of patients with debilitating diseases.
Andrea Cotton
Andrea Cotton-Berry

Global Head of Strategic Development, Precision for Medicine

Notable authority in global operations, dedicated to fostering team spirit of excellence and collaboration with internal and external partners. Veteran of the quest to improve oncology therapies and extend lives, including 15+ years in oncology drug development, building on 10 years in obstetrics and women’s health.